Institute of Medical Sciences, Faculty of Medicine, University of Liverpool, Liverpool, UK.
Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA.
Ren Fail. 2020 Nov;42(1):489-494. doi: 10.1080/0886022X.2020.1759636.
: The aim of our study is to explore the relationship of rabbit anti-thymocyte globulin (R-ATG) on development of post-transplant lymphoproliferative disease (PTLD) and its aggressive forms (monomorphic PTLD and Hodgkin lymphoma) in renal transplant recipients.: All patients diagnosed with PTLD post-renal transplant in the United States' Organ Procurement and Transplantation Network from 2003 till 2013 and followed up till 2017 were retrospectively reviewed. Multi-variable logistic regression analysis assessed association of R-ATG to development of PTLD and its aggressive form.: Risk of developing PTLD post renal transplant is 1.35%. In comparison to interleukin-2 blocker induction therapy, R-ATG is associated with increased risk of development of PTLD (Odds Ratio = 1.48, confidence interval ranges from 1.04 to 2.11, = .02) and is associated with higher risk of development of aggressive PTLD (Odds Ratio = 1.83, confidence interval ranges from 1.001 to 3.34, = .04).: We conclude that R-ATG induction is associated with a higher risk of PTLD and its aggressive form (monomorphic PTLD and Hodgkin lymphoma). Careful monitoring for development of PTLD in renal transplant recipients receiving R-ATG induction therapy is advised.
: 我们的研究目的是探讨兔抗胸腺细胞球蛋白（R-ATG）与肾移植受者移植后淋巴组织增生性疾病（PTLD）及其侵袭性形式（单形性 PTLD 和霍奇金淋巴瘤）发展之间的关系。
: 回顾性分析了 2003 年至 2013 年期间美国器官获取与移植网络中诊断为肾移植后 PTLD 并随访至 2017 年的所有患者。多变量逻辑回归分析评估了 R-ATG 与 PTLD 及其侵袭性形式发展的相关性。
: 肾移植后发生 PTLD 的风险为 1.35%。与白细胞介素-2 阻滞剂诱导治疗相比，R-ATG 与 PTLD 发展的风险增加相关（优势比=1.48，置信区间范围为 1.04 至 2.11，=0.02），与侵袭性 PTLD 发展的风险增加相关（优势比=1.83，置信区间范围为 1.001 至 3.34，=0.04）。
: 我们得出结论，R-ATG 诱导与 PTLD 及其侵袭性形式（单形性 PTLD 和霍奇金淋巴瘤）的风险增加相关。建议接受 R-ATG 诱导治疗的肾移植受者仔细监测 PTLD 的发展。
